The efficacy and safety research of sacubitril/valsartan in HF with preserved ejection fraction in patients on maintenance dialysis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400092130

Enrollment

Unknown

Registered

2024-11-11

Start date

2022-07-22

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure with preserved ejection fraction (HFpEF) in patients on maintenance dialysis

Interventions

Group A:standard HF treatments+sacubitril-valsartan

Group B:standard HF treatments+valsartan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1)Adult individuals aged 18 or above; (2) Undergoing maintenance hemodialysis (HD) or peritoneal dialysis (PD) or both for more than 3 months; (3)Meeting the New York Heart Association's classification of heart function II-IV; (4)Having an ejection fraction of 50% or higher, confirmed by cardiac ultrasound with diastolic dysfunction; (5)Level of N-terminal pro–B-type natriuretic peptide (NT-proBNP)=600pg/ml.

Exclusion criteria

Exclusion criteria: (1)Hypotension: Systolic blood pressure<100mmHg;(2)Inadequate dialysis; (3) Angioedema or allergy caused by ARBs (angiotensin-receptor blockers).

Design outcomes

Primary

Measure	Time frame
improvement in NYHA functional class;LVEF; 6-minute walking test;	—

Secondary

Measure	Time frame
Heart rate;level?of?N-terminal pro-brain natriuretic peptide(NT-proBNP);	—

Countries

China

Contacts

Public ContactXiaoying Ding

Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine

ringdxy@163.com+86 138 2561 3071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026